Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCR | P30988 | 4/20 | 0.57 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.56 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.54 |
| ▸ | F2 | P00734 | 4/20 | 0.54 |
| ▸ | TFPI | P10646 | 1/20 | 0.53 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.53 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | NPY2R | P49146 | 1/20 | 0.52 |
| ▸ | NPY4R | P50391 | 1/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30432401 | 0.88 | CALCR (0.61) | CALCRCRHR1CRHR2OPRD1NPY1R | |
| SCHEMBL30262116 | 0.87 | F2 (0.62) | CALCROPRD1F2TFPINPY1R | |
| SCHEMBL31182439 | 0.86 | CALCR (0.63) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL29558249 | 0.86 | OPRD1 (0.59) | CALCRCRHR1CRHR2OPRD1OPRM1 | |
| SCHEMBL30432109 | 0.86 | CALCR (0.69) | CALCRCRHR1CRHR2F2TFPI | |
| SCHEMBL29679496 | 0.86 | CALCR (0.61) | CALCRCRHR1CRHR2F2TFPI | |
| SCHEMBL30437162 | 0.85 | F2 (0.60) | CALCRCRHR1CRHR2OPRD1F2 | |
| SCHEMBL30176416 | 0.85 | NPY2R (0.62) | F2TFPINPY1RNPY2RNPY4R | |
| SCHEMBL30432005 | 0.85 | CALCR (0.62) | CALCRCRHR1CRHR2F2TFPI | |
| SCHEMBL31182450 | 0.84 | NPY2R (0.66) | CALCRTFPINPY1RNPY2RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081259-A1 | VIRUS-MIMETIC NANOPARTICLES | Universität Regensburg (DE) | 2022-11-02 | — | — | EP | claimed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-116849231-A | Pest control composition and use thereof | 旗舰创业创新六公司 | 2023-10-10 | — | — | CN | disclosed |
| CN-112469281-B | Pest control composition and use thereof | 旗舰创业创新六公司 | 2023-05-30 | — | — | CN | disclosed |
| EP-4081259-A1 | VIRUS-MIMETIC NANOPARTICLES | Universität Regensburg (DE) | 2022-11-02 | — | — | EP | disclosed |
| US-20220135640-A1 | CORTISTATIN OR AN ANALOGUE THEREOF AS A PHARMACEUTICALLY ACTIVE AGENT IN LATENT FORM | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) | 2022-05-05 | — | — | US | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CALCR 894/4885CRHR1 3476/4885CRHR2 3111/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | CALCR 894/4885CRHR1 3476/4885CRHR2 3111/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | CALCR 801/4885CRHR1 2481/4885CRHR2 2222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.